KEYTRUDA® (Pembrolizumab) Enhances Disease-Free Survival (DFS) as Adjuvant in High-Risk Urothelial Carcinoma Post-Surgery.

Dupixent® has been granted FDA approval as the exclusive therapy indicated for pediatric patients over the age of 1 diagnosed with eosinophilic esophagitis (EoE).

Orion Presents New Insights from Phase II CYPIDES Trial on ODM-208 at 2024 ASCO Symposium.

CBR-701 (SYS6002), a cutting-edge therapeutic agent aimed at Nectin-4, exhibits promising outcomes in initial human trials with Nectin-4 positive cancer patients.

Flare Therapeutics Unveils Design for FX-909's Early-Stage Trial with Dose Increasing and Widening Approach at ASCO's 2024 Urologic Cancer Conference.

LAVA Therapeutics reveals a partnership with Merck & Co., US, to assess the potential of combining LAVA-1207 with the treatment, KEYTRUDA®.

Sionna Therapeutics has revealed the administration of the initial dose to a healthy participant in the Stage 1 clinical study for SION-109.

Sciwind Biosciences Reports Encouraging Outcomes from Initial Clinical Study of XW004, Its Oral Version of Sustained-Release GLP-1 Mimetic Ecnoglutide.

Locus Biosciences has disclosed receiving a $23.9 million investment from BARDA, intended to back the inaugural Phase 2 study of its groundbreaking CRISPR-crafted phage treatment.

Onward Therapeutics has begun recruiting for an initial phase clinical study of their innovative dual-targeted antibody, OT-A201, which engages with two distinct immune control points.

PharmAbcine Initiates Dosing in Early-Stage Study for PMC-309 with KEYTRUDA (pembrolizumab) in Subjects Facing Severe Solid Cancers.

Harbour BioMed has been granted FDA approval to initiate human trials for their bispecific antibody, HBM9027, in the U.S.